JP2013543518A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013543518A5 JP2013543518A5 JP2013534305A JP2013534305A JP2013543518A5 JP 2013543518 A5 JP2013543518 A5 JP 2013543518A5 JP 2013534305 A JP2013534305 A JP 2013534305A JP 2013534305 A JP2013534305 A JP 2013534305A JP 2013543518 A5 JP2013543518 A5 JP 2013543518A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical
- composition according
- veterinary composition
- amount
- bioadhesive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 19
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 8
- 239000000227 bioadhesive Substances 0.000 claims 6
- 239000002904 solvent Substances 0.000 claims 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 4
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 claims 3
- 229960003128 mupirocin Drugs 0.000 claims 3
- 229930187697 mupirocin Natural products 0.000 claims 3
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical group O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 229940057917 medium chain triglycerides Drugs 0.000 claims 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims 1
- 239000004264 Petrolatum Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 229940074928 isopropyl myristate Drugs 0.000 claims 1
- 229940066842 petrolatum Drugs 0.000 claims 1
- 235000019271 petrolatum Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229940042129 topical gel Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10382274.8 | 2010-10-20 | ||
| EP10382274A EP2444067A1 (en) | 2010-10-20 | 2010-10-20 | Anhydrous gel comprising mupirocin |
| PCT/EP2011/068242 WO2012052472A1 (en) | 2010-10-20 | 2011-10-19 | Pharmaceutical topical composition of mupirocin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013543518A JP2013543518A (ja) | 2013-12-05 |
| JP2013543518A5 true JP2013543518A5 (enExample) | 2014-12-04 |
| JP5954745B2 JP5954745B2 (ja) | 2016-07-20 |
Family
ID=44050874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013534305A Active JP5954745B2 (ja) | 2010-10-20 | 2011-10-19 | ムピロシンの局所用薬学的組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9205149B2 (enExample) |
| EP (2) | EP2444067A1 (enExample) |
| JP (1) | JP5954745B2 (enExample) |
| KR (1) | KR101776362B1 (enExample) |
| CN (1) | CN103189048B (enExample) |
| AU (1) | AU2011317636B2 (enExample) |
| BR (1) | BR112013009371B1 (enExample) |
| CA (1) | CA2814103C (enExample) |
| ES (1) | ES2531846T3 (enExample) |
| MX (1) | MX2013004394A (enExample) |
| NZ (1) | NZ609655A (enExample) |
| PL (1) | PL2629756T3 (enExample) |
| PT (1) | PT2629756E (enExample) |
| RU (1) | RU2563840C2 (enExample) |
| WO (1) | WO2012052472A1 (enExample) |
| ZA (1) | ZA201302560B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150027831A (ko) * | 2012-07-06 | 2015-03-12 | 레오 파마 에이/에스 | 피부에 활성 성분을 전달하기 위한 막-형성 중합체를 포함하는 국소 조성물 |
| EP2742932A1 (en) | 2012-12-17 | 2014-06-18 | Laboratorios Ojer Pharma S.L. | Gel compositions |
| WO2016133471A1 (en) | 2015-02-20 | 2016-08-25 | Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A. Ş. | A topical composition comprising mupirocin and dexpanthenol |
| EP3346998B1 (en) | 2015-08-17 | 2025-04-16 | Sidmak Laboratories (India) PVT. Ltd. | Topical film delivery system |
| KR101717699B1 (ko) | 2016-02-11 | 2017-03-17 | 아이큐어 주식회사 | 카타플라스마제용 자외선 경화형 하이드로젤 수지, 하이드로젤 및 이를 포함하는 카타플라스마제 |
| WO2020141482A1 (en) * | 2019-01-04 | 2020-07-09 | Glenmark Specialty S.A. | Pharmaceutical compositions comprising mupirocin |
| CN110090198B (zh) * | 2019-05-09 | 2020-02-21 | 哈尔滨乾佰纳生物药业有限公司 | 一种具有生物粘附性的缓释型口腔溃疡凝胶及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8530796D0 (en) * | 1985-12-13 | 1986-01-22 | Beecham Group Plc | Pharmaceutical composition |
| IE59628B1 (en) | 1986-06-26 | 1994-03-09 | Beecham Group Plc | Treatment of fungal infections |
| GB8615669D0 (en) * | 1986-06-26 | 1986-07-30 | Beecham Group Plc | Treatment |
| GB9321876D0 (en) * | 1993-10-22 | 1993-12-15 | Smithkline Beecham Corp | Novel composition |
| AUPO379596A0 (en) | 1996-11-22 | 1996-12-19 | Soltec Research Pty Ltd | Percutaneous delivery system |
| WO1999012520A1 (en) * | 1997-09-11 | 1999-03-18 | Smithkline Beecham Plc | Compositions adapted for prolonged residence in the nasal pharynx |
| IL137363A (en) | 2000-07-18 | 2005-12-18 | Agis Ind 1983 Ltd | Pharmaceutical compositions containing mupirocin |
| AU2002950506A0 (en) * | 2002-07-31 | 2002-09-12 | Soltec Research Pty Ltd | Percutaneous delivery system |
| US7820145B2 (en) * | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US8486374B2 (en) * | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
| US20050123576A1 (en) * | 2003-12-03 | 2005-06-09 | Ilana Lavon | Mupirocin compositions for topical use, an improved process of making same and methods of using same |
| KR20070080823A (ko) * | 2007-01-31 | 2007-08-13 | 주식회사 티디에스팜 | 활성약물 함유 상처 치료용 하이드로겔 제제 |
-
2010
- 2010-10-20 EP EP10382274A patent/EP2444067A1/en not_active Withdrawn
-
2011
- 2011-10-19 CN CN201180050316.6A patent/CN103189048B/zh active Active
- 2011-10-19 MX MX2013004394A patent/MX2013004394A/es active IP Right Grant
- 2011-10-19 EP EP11770791.9A patent/EP2629756B1/en active Active
- 2011-10-19 ES ES11770791.9T patent/ES2531846T3/es active Active
- 2011-10-19 WO PCT/EP2011/068242 patent/WO2012052472A1/en not_active Ceased
- 2011-10-19 JP JP2013534305A patent/JP5954745B2/ja active Active
- 2011-10-19 KR KR1020137011960A patent/KR101776362B1/ko active Active
- 2011-10-19 PT PT117707919T patent/PT2629756E/pt unknown
- 2011-10-19 US US13/879,008 patent/US9205149B2/en active Active
- 2011-10-19 BR BR112013009371A patent/BR112013009371B1/pt active IP Right Grant
- 2011-10-19 CA CA2814103A patent/CA2814103C/en active Active
- 2011-10-19 RU RU2013122845/15A patent/RU2563840C2/ru active
- 2011-10-19 NZ NZ609655A patent/NZ609655A/en unknown
- 2011-10-19 AU AU2011317636A patent/AU2011317636B2/en active Active
- 2011-10-19 PL PL11770791T patent/PL2629756T3/pl unknown
-
2013
- 2013-04-09 ZA ZA2013/02560A patent/ZA201302560B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013543518A5 (enExample) | ||
| ES2409069B2 (es) | Uso de aglutinantes para fabricar formulaciones estables al almacenamiento | |
| AR080491A1 (es) | Formulaciones orales y sales lipofilicas de metilnaltrexona | |
| HRP20250119T1 (hr) | Kdm1a inhibitor i njegova primjena u terapiji | |
| CO6321225A2 (es) | Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico | |
| HRP20160605T1 (hr) | Tetraciklički spoj | |
| EA201100358A1 (ru) | Дабигатран для чрескожной хирургической катетеризации сердца | |
| EP2643002A4 (en) | PHARMACEUTICAL FORMULATIONS WITH CORTICOSTEROIDS FOR TOPICAL ADMINISTRATION | |
| HUE052378T2 (hu) | Lokális topikális adagolású, indoxacarb tartalmú formulációk | |
| JP2010535814A5 (enExample) | ||
| MX342212B (es) | Inhibidores de neprilisina. | |
| CL2009000882A1 (es) | Un compuesto n-(4-cloro-3-(piridin-2-il)fenil)-4-(2-hidroxi-2-metilpropilsulfonil)-2-metilbenzamida, inhibidor de la via de señalización hedgehog; composición farmacéutica que comprende a dicho compuesto; y su uso para tratar el cancer. | |
| AR084691A1 (es) | Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel | |
| ECSP10010167A (es) | Composiciones oftálmicas novedosas | |
| WO2016034946A3 (en) | Thienopyrroles as histone demethylase inhibitors | |
| CN103717571B8 (zh) | 9‑氨基甲基取代的四环素类化合物 | |
| CR9703A (es) | Derivados de pirazolona | |
| MA34055B1 (fr) | Chlorhydrate d'agomelatine hydrate et sa preparation | |
| CO6361855A2 (es) | Derivados de 7-hidroxi-benzoimidazol-4-il-,etanona e inhibidores de cinasa que enlaza pdz que contienen los mismos | |
| CL2015000375A1 (es) | Composicion farmaceutica en forma de microparticulas que comprende un nucleo inerte y al menos una primera capa de principio activo; proceso de formacion de microparticulas; combinacion farmaceutica; kit farmaceutico; uso para tratar y/o prevenir edemas, enfermedades cardiovasculares, diabetes, hipertension, entre otras. | |
| RU2013122845A (ru) | Фармацевтическая композиция мупироцина для местного применения | |
| CL2010000524A1 (es) | Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales. | |
| CL2013000895A1 (es) | Combinacion farmaceutica que comprende un compuesto derivado de imidazo[4,5-c]-quinolina, inhibidor de pik3/mtor, un compuesto alosterico inhibidor de mtor y opcionalmente un vehiculo farmaceuticamente aceptable; composicion farmaceutica; metodo para mejorar la eficacia del tratamiento; y su uso en una enfermedad proliferativa. | |
| JP2005527551A5 (enExample) | ||
| WO2009120389A8 (en) | Oral and injectable formulations of tetracycline compounds |